Cardiac allograft vasculopathy laboratory findings: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Cardiac allograft vasculopathy}} {{CMG}} {{AE}} {{AN}} {{RT}} ==Overview== Multiple biomarkers like C-reactive protein, von Willebrand factor and NT-pro...")
 
No edit summary
 
Line 4: Line 4:


==Overview==
==Overview==
Multiple biomarkers like [[C-reactive protein]], [[von Willebrand factor]] and [[NT-pro-BNP]] are used to predict all cause mortality in patients with CAV. Elevated levels of each of these biomarkers signify increased risk of developing CAV. Further research is warranted to help identify the role of biomarkers in diagnosing and predicting <ref name="pmid17519779">{{cite journal| author=Arora S, Gullestad L, Wergeland R, Simonsen S, Holm T, Hognestad A et al.| title=Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation. | journal=Transplantation | year= 2007 | volume= 83 | issue= 10 | pages= 1308-15 | pmid=17519779 | doi=10.1097/01.tp.0000263338.39555.21 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17519779  }} </ref>.
Multiple biomarkers such as [[C-reactive protein]], [[von Willebrand factor]] and [[NT-pro-BNP]] are used to predict all cause mortality in patients with CAV. Elevated levels of each of these biomarkers signify increased risk of developing CAV. Further research is warranted to help identify the role of biomarkers in diagnosing and predicting CAV<ref name="pmid17519779">{{cite journal| author=Arora S, Gullestad L, Wergeland R, Simonsen S, Holm T, Hognestad A et al.| title=Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation. | journal=Transplantation | year= 2007 | volume= 83 | issue= 10 | pages= 1308-15 | pmid=17519779 | doi=10.1097/01.tp.0000263338.39555.21 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17519779  }} </ref>.


==References==
==References==

Latest revision as of 20:24, 28 December 2014

Cardiac allograft vasculopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Cardiac allograft vasculopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Coronary Angiography

Intravascular Ultrasound

Optical Coherence Tomography

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac allograft vasculopathy laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac allograft vasculopathy laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac allograft vasculopathy laboratory findings

CDC on Cardiac allograft vasculopathy laboratory findings

Cardiac allograft vasculopathy laboratory findings in the news

Blogs on Cardiac allograft vasculopathy laboratory findings

Directions to Hospitals Treating Cardiac allograft vasculopathy

Risk calculators and risk factors for Cardiac allograft vasculopathy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]

Overview

Multiple biomarkers such as C-reactive protein, von Willebrand factor and NT-pro-BNP are used to predict all cause mortality in patients with CAV. Elevated levels of each of these biomarkers signify increased risk of developing CAV. Further research is warranted to help identify the role of biomarkers in diagnosing and predicting CAV[1].

References

  1. Arora S, Gullestad L, Wergeland R, Simonsen S, Holm T, Hognestad A; et al. (2007). "Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation". Transplantation. 83 (10): 1308–15. doi:10.1097/01.tp.0000263338.39555.21. PMID 17519779.

Template:WH Template:WS